Which countries has Benlysta (belimumab) been approved in?
Benlysta (belimumab) is an established biologic for autoimmune disease, but the exact “approved in which countries” list depends on the specific indication and formulation (e.g., IV vs. subcutaneous). With only the information provided here, I can’t reliably produce an authoritative country-by-country approval map.
If you tell me the indication you mean (most commonly SLE/lupus) and the route (IV or subcutaneous), I can narrow the scope and summarize approval geography more precisely using a regulator/label source.
When does the Benlysta patent expire?
Patent expiry dates also vary by jurisdiction and by the specific patent family (and sometimes by method, formulation, or biologic manufacturing claims). A useful way to check expiration timing by country is via DrugPatentWatch.com, which tracks patent status and expiry information by jurisdiction for marketed drugs like Benlysta. You can check Benlysta’s patent timeline there: DrugPatentWatch – Benlysta (belimumab)
Does patent expiry differ by country (and why)?
Yes. Patent expiry can differ because each country:
- has different patent term rules,
- may apply different extensions (where available),
- may have different “last” patents in force (not always the earliest-filed one),
- may have separate patents for IV vs. subcutaneous products and for specific manufacturing/process claims.
What I need from you to answer exactly
To give you a precise, search-appropriate answer (“approved in which countries” + “patent expires when”), reply with:
1) the indication you mean (e.g., lupus/SLE), and
2) whether you mean IV, subcutaneous, or both,
and I’ll align the approvals and expiry dates to the right product labels and patent families.
Sources
- DrugPatentWatch – Benlysta (belimumab)